CardioNXT Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$13M
- Investors
-
5
CardioNXT General Information
Description
Developer of an AI-based precision therapy designed to detect cardiac arrhythmias. The company's therapy improves outcomes in the treatment of cardiac arrhythmias such as chronic atrial fibrillation, enabling people to adopt arrhythmia therapies in global markets as well as in the underserved emerging markets.
Contact Information
Website
www.cardionxt.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 12011 North Tejon Street
- Suite 700, Westminster
- Denver, CO 80234
- United States
+1 (720) 000-0000
CardioNXT Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 29-Jul-2019 | $13M | 000.00 | 0000 | Completed | Clinical Trials - General |
| 4. Early Stage VC (Series B) | 01-Jun-2017 | 00.00 | 00.00 | 000.00 | Completed | Clinical Trials - General |
| 3. Early Stage VC (Series A1) | 31-May-2016 | 00.00 | 00.00 | 00.00 | Completed | Clinical Trials - General |
| 2. Grant | 14-May-2015 | $250K | $1M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 22-Aug-2012 | $1M | $1M | 00.00 | Completed | Startup |
CardioNXT Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A | 6,697,488 | $0.001000 | 6% | $0.15 | $0.15 | 1x | $0.15 | 24.37% |
CardioNXT Patents
CardioNXT Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190000339-A1 | Systems, apparatus, and methods for electro-anatomical mapping of a catheter with electrode contact assessment and rotor projection | Pending | 27-Jul-2015 | ||
| EP-3119276-A1 | System and methods for using body surface cardiac electrogram information combined with internal information to deliver therapy | Pending | 19-Mar-2014 | 000000000 | |
| US-20150320515-A1 | System and methods for using body surface cardiac electrogram information combined with internal information to deliver therapy | Inactive | 19-Mar-2014 | 000000000 | |
| EP-3119276-A4 | System and methods for using body surface cardiac electrogram information combined with internal information to deliver therapy | Pending | 19-Mar-2014 | 000000000 | |
| EP-3824806-A1 | System and method for localizing medical instruments during cardiovascular medical procedures | Pending | 10-Apr-2012 | A61B5/063 |
CardioNXT Executive Team (5)
CardioNXT Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Donald Conty JD | CardioNXT | Chief Financial Officer, General Counsel & Board Member | 000 0000 |
| Jerome Edwards | CardioNXT | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
CardioNXT Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
CardioNXT Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| James W. Bullock | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Piedmont Capital Partners | Real Estate | Minority | 000 0000 | 000000 0 | |
| William Hawkins | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Solas BioVentures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Office of Economic Development and International Trade | Government | 000 0000 | 000000 0 |